Exact Mass: 546.2155
Exact Mass Matches: 546.2155
Found 500 metabolites which its exact mass value is equals to given mass value 546.2155
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
asukamycin
A polyketide that is a member of the manumycin family of antibiotics and exhibits strong antibacterial, antifungal, and antineoplastic activities. Isolated from from the actinomycete bacterium Streptomyces nodosus subsp. asukaensis.
Physagulin B
Constituent of the famine food Physalis angulata (cutleaf ground cherry). Physagulin B is found in herbs and spices and fruits. Physagulin B is found in fruits. Physagulin B is a constituent of the famine food Physalis angulata (cutleaf ground cherry).
Farglitazar
Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-
Tryptoquivaline
(2S)-2-[(4-Methylphenyl)sulfonylamino]-3-[[4-oxo-5-(2-piperidin-4-ylethyl)-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepine-2-carbonyl]amino]propanoic acid
PA(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))
PA(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0)
PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/2:0), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
[3S-(3alpha,5alpha,5aalpha,6alpha,9beta,9aalpha,10S*)]-5,10-bis(Acetyloxy)-5a-[(acetyloxy)methyl]-6-(benzoyloxy)octahydro-9-hydroxy-2,2,9-trimethyl-4H-3,9a-methano-1-benzoxepin-4-one
(2E)-2,3-didehydro-3-deoxy-maytansinol|(3E,5E,7R,84S,12E)-14-chloro-10t,11c-epoxy-84-hydroxy-15,7r-dimethoxy-3,9c,11t,15-tetramethyl-(84rH,86cH)-15-aza-1(1,3)-benzena-8(4,6)-[1,3]oxazinana-cyclopentadecaphane-3,5,12-triene-82,14-dione|Maysin|Maysin (5)|maysine
erythro-1-(4-hydroxy-3-methoxyphenyl)-2-<4-(3-hydroxypropyl)-2-methoxyphenoxy>propane-1,3-diol tetraacetate|threo-1-(4-hydroxy-3-methoxyphenyl)-2-<4-(3-hydroxypropyl)-2-methoxyphenoxy>propane-1,3-diol tetraacetate
Benzyl glycoside,6-O-benzylidene,2-Ac-beta-Pyranose-3-O-alpha-L-Rhamnopyranosyl-D-galactose
Pyrano[4,3:4,5]azepino[1,2:1,2]pyrido[3,4-b]indole-1-carboxylic acid, 4-(beta-D-glucopyranosyloxy)-4,4a,5,6,8,9,14,14b,15,15a-decahydro-5-hydroxy-, methyl ester, (4S,4aS,5S,14bS,15aS)-
10,11-dimethoxy-1-methyl-deacetyl picraline benzoate
(1R,2S,4R,5S,6R,7R,9S,10S)-9-benzoyloxy-1-hydroxy-2,6,15-triacetoxy-8-oxo-dihydro-beta-agarofuran
1-O-deacetyl-2alpha-methoxylkhayanolide E|khayseneganin G
4,C4-dihydro-4-hydroxy-8-oxo-beta-agarofuran-1alpha,2alpha,6beta,9alpha-tetrayl 1alpha,2alpha,6beta-triacetate 9alpha-benzoate
(2S)-1-acetoxy-4t-[2-((S)-1-hydroxy-2-methyl-propyl)-4-oxo-4H-quinazolin-3-yl]-2,2-dimethyl-(2rC8a,9rO,9at)-3,4,1,9a-tetrahydro-2H-spiro[furan-2,9-imidazo[1,2-a]indole]-5,3-dione|Isotryptoquivalin|Isotryptoquivaline|Tryptoquivalin C
4,6-dimethyl-5-O-[alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranosyl]multifidol
His Phe Glu Asp
Gln Arg Asp Glu
Phe Glu His Asp
7-(5-formyl-3,6-dihydroxy-7-methoxy-1-methyl-8-propan-2-ylnaphthalen-2-yl)-2,8-dihydroxy-3-methoxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
C27H35ClN4O6_2(6H)-Isoquinolineacetic acid, 7-(acetyloxy)-alpha-[3-[(aminoiminomethyl)amino]propyl]-5-chloro-3-[(1E,3E)-3,5-dimethyl-1,3-heptadien-1-yl]-7,8-dihydro-7-methyl-6,8-dioxo
Farglitazar
CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5746; ORIGINAL_PRECURSOR_SCAN_NO 5743 C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5760; ORIGINAL_PRECURSOR_SCAN_NO 5756 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5717; ORIGINAL_PRECURSOR_SCAN_NO 5714 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5752; ORIGINAL_PRECURSOR_SCAN_NO 5748 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5751; ORIGINAL_PRECURSOR_SCAN_NO 5750 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5754; ORIGINAL_PRECURSOR_SCAN_NO 5753 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10453; ORIGINAL_PRECURSOR_SCAN_NO 10449 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10505; ORIGINAL_PRECURSOR_SCAN_NO 10503 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10516; ORIGINAL_PRECURSOR_SCAN_NO 10511 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10552; ORIGINAL_PRECURSOR_SCAN_NO 10548 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10569; ORIGINAL_PRECURSOR_SCAN_NO 10567 CONFIDENCE standard compound; INTERNAL_ID 508; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10577; ORIGINAL_PRECURSOR_SCAN_NO 10575
Ala Met Tyr Tyr
Ala Tyr Met Tyr
Ala Tyr Tyr Met
Cys Phe Phe Met
Cys Phe Met Phe
Cys Met Phe Phe
Cys Val Tyr Tyr
Cys Tyr Val Tyr
Cys Tyr Tyr Val
Asp Glu Phe His
Asp Glu His Phe
Asp Glu Gln Arg
Asp Glu Arg Gln
Asp Phe Glu His
Asp Phe His Glu
Asp His Glu Phe
Asp His Phe Glu
Asp Gln Glu Arg
Asp Gln Arg Glu
Asp Arg Glu Gln
Asp Arg Gln Glu
Asp Ser Tyr Tyr
Asp Tyr Ser Tyr
Asp Tyr Tyr Ser
Glu Asp Phe His
Glu Asp His Phe
Glu Asp Gln Arg
Glu Asp Arg Gln
Glu Glu Asn Arg
Glu Glu Arg Asn
Glu Phe Asp His
Glu Phe His Asp
Glu His Asp Phe
Glu His Phe Asp
Glu His Met Met
Glu Met His Met
Glu Met Met His
Glu Asn Glu Arg
Glu Asn Arg Glu
Glu Gln Asp Arg
Glu Gln Arg Asp
Glu Arg Asp Gln
Glu Arg Glu Asn
Glu Arg Asn Glu
Glu Arg Gln Asp
Phe Cys Phe Met
Phe Cys Met Phe
Phe Asp Glu His
Phe Asp His Glu
Phe Glu Asp His
Phe Phe Cys Met
Phe Phe Met Cys
Phe His Asp Glu
Phe His Glu Asp
Phe Met Cys Phe
Phe Met Phe Cys
Phe Met Ser Tyr
Phe Met Tyr Ser
Phe Ser Met Tyr
Phe Ser Tyr Met
Phe Tyr Met Ser
Phe Tyr Ser Met
His Asp Glu Phe
His Asp Phe Glu
His Glu Asp Phe
His Glu Phe Asp
His Glu Met Met
His Phe Asp Glu
His Ile Tyr Asp
His Met Glu Met
His Met Met Glu
His Met Pro Tyr
His Met Tyr Pro
His Asn Asn Tyr
His Asn Tyr Asn
His Pro Met Tyr
His Pro Tyr Met
His Tyr Met Pro
His Tyr Asn Asn
His Tyr Pro Met
Leu Tyr His Asp
Met Ala Tyr Tyr
Met Cys Phe Phe
Met Glu His Met
Met Glu Met His
Met Phe Cys Phe
Met Phe Phe Cys
Met Phe Ser Tyr
Met Phe Tyr Ser
Met His Glu Met
Met His Met Glu
Met His Pro Tyr
Met His Tyr Pro
Met Met Glu His
Met Met His Glu
Met Asn Pro Trp
Met Asn Trp Pro
Met Pro His Tyr
Met Pro Asn Trp
Met Pro Trp Asn
Met Pro Tyr His
Met Ser Phe Tyr
Met Ser Tyr Phe
Met Trp Asn Pro
Met Trp Pro Asn
Met Tyr Ala Tyr
Met Tyr Phe Ser
Met Tyr His Pro
Met Tyr Pro His
Met Tyr Ser Phe
Met Tyr Tyr Ala
Asn Asp Ile Trp
Asn Asp Leu Trp
Asn Asp Trp Ile
Asn Asp Trp Leu
Asn Glu Glu Arg
Asn Glu Arg Glu
Asn Glu Val Trp
Asn Glu Trp Val
Asn His Asn Tyr
Asn His Tyr Asn
Asn Ile Asp Trp
Asn Ile Trp Asp
Asn Leu Asp Trp
Asn Leu Trp Asp
Asn Met Pro Trp
Asn Met Trp Pro
Asn Asn His Tyr
Asn Asn Asn Trp
Asn Asn Trp Asn
Asn Asn Tyr His
Asn Pro Met Trp
Asn Pro Trp Met
Asn Arg Glu Glu
Asn Val Glu Trp
Asn Val Trp Glu
Asn Trp Asp Ile
Asn Trp Asp Leu
Asn Trp Glu Val
Asn Trp Ile Asp
Asn Trp Leu Asp
Asn Trp Met Pro
Asn Trp Asn Asn
Asn Trp Pro Met
Asn Trp Val Glu
Asn Tyr His Asn
Asn Tyr Asn His
Pro His Met Tyr
Pro His Tyr Met
Pro Met His Tyr
Pro Met Asn Trp
Pro Met Trp Asn
Pro Met Tyr His
Pro Asn Met Trp
Pro Asn Trp Met
Pro Trp Met Asn
Pro Trp Asn Met
Pro Tyr His Met
Pro Tyr Met His
Gln Asp Glu Arg
Gln Asp Arg Glu
Gln Asp Val Trp
Gln Asp Trp Val
Gln Glu Asp Arg
Gln Glu Arg Asp
Gln Arg Glu Asp
Gln Val Asp Trp
Gln Val Trp Asp
Gln Trp Asp Val
Gln Trp Val Asp
Arg Asp Glu Gln
Arg Asp Gln Glu
Arg Glu Asp Gln
Arg Glu Glu Asn
Arg Glu Asn Glu
Arg Glu Gln Asp
Arg Asn Glu Glu
Arg Gln Asp Glu
Arg Gln Glu Asp
Ser Asp Tyr Tyr
Ser Phe Met Tyr
Ser Phe Tyr Met
Ser Met Phe Tyr
Ser Met Tyr Phe
Ser Tyr Asp Tyr
Ser Tyr Phe Met
Ser Tyr Met Phe
Ser Tyr Tyr Asp
Thr Thr Tyr Tyr
Thr Tyr Thr Tyr
Thr Tyr Tyr Thr
Val Cys Tyr Tyr
Val Asp Gln Trp
Val Asp Trp Gln
Val Glu His Tyr
Val Glu Asn Trp
Val Glu Trp Asn
Val Glu Tyr His
Val His Glu Tyr
Val His Tyr Glu
Val Asn Glu Trp
Val Asn Trp Glu
Val Gln Asp Trp
Val Gln Trp Asp
Val Trp Asp Gln
Val Trp Glu Asn
Val Trp Asn Glu
Val Trp Gln Asp
Val Tyr Cys Tyr
Val Tyr Glu His
Val Tyr His Glu
Val Tyr Tyr Cys
Trp Asp Ile Asn
Trp Asp Leu Asn
Trp Asp Asn Ile
Trp Asp Asn Leu
Trp Asp Gln Val
Trp Asp Val Gln
Trp Glu Asn Val
Trp Glu Val Asn
Trp Ile Asp Asn
Trp Ile Asn Asp
Trp Leu Asp Asn
Trp Leu Asn Asp
Trp Met Asn Pro
Trp Met Pro Asn
Trp Asn Asp Ile
Trp Asn Asp Leu
Trp Asn Glu Val
Trp Asn Ile Asp
Trp Asn Leu Asp
Trp Asn Met Pro
Trp Asn Asn Asn
Trp Asn Pro Met
Trp Asn Val Glu
Trp Pro Met Asn
Trp Pro Asn Met
Trp Gln Asp Val
Trp Gln Val Asp
Trp Val Asp Gln
Tyr Ala Met Tyr
Tyr Ala Tyr Met
Tyr Cys Val Tyr
Tyr Cys Tyr Val
Tyr Asp Ser Tyr
Tyr Asp Tyr Ser
Tyr Phe Met Ser
Tyr Phe Ser Met
Tyr His Met Pro
Tyr His Asn Asn
Tyr His Pro Met
Tyr Met Ala Tyr
Tyr Met Phe Ser
Tyr Met His Pro
Tyr Met Pro His
Tyr Met Ser Phe
Tyr Met Tyr Ala
Tyr Asn His Asn
Tyr Asn Asn His
Tyr Pro His Met
Tyr Pro Met His
Tyr Ser Asp Tyr
Tyr Ser Phe Met
Tyr Ser Met Phe
Tyr Ser Tyr Asp
Tyr Thr Thr Tyr
Tyr Thr Tyr Thr
Tyr Val Cys Tyr
Tyr Val Tyr Cys
Tyr Tyr Ala Met
Tyr Tyr Cys Val
Tyr Tyr Asp Ser
Tyr Tyr Met Ala
Tyr Tyr Ser Asp
Tyr Tyr Thr Thr
Tyr Tyr Val Cys
Physagulin B
Physagulin B
Methyl [(2S)-1-[(2S,5S)-2-[9-chloro-1,11-dihydroisochromeno[4,3:6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
(4Z)-N-(2-methoxyphenyl)-4-[[2-methoxy-5-(phenylcarbamoyl)phenyl]hydrazinylidene]-3-oxonaphthalene-2-carboxamide
Linerixibat
C78276 - Agent Affecting Digestive System or Metabolism > C177170 - Ileal Bile Acid Transport Inhibitor
Tepotinib Hydrochloride Hydrate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164000 - c-Met-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D000970 - Antineoplastic Agents
Bistratamide E
A homodetic cyclic peptide that consists of L-threonine and L-valine as the amino acid residues cyclised via amide bonds. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line.
7-(8-Formyl-1,7-dihydroxy-5-isopropyl-6-methoxy-3-methyl-2-naphthyl)-2,8-dihydroxy-4-isopropyl-3-methoxy-6-methyl-naphthalene-1-carbaldehyde
Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-
(E)-2-cyano-N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-[9-methyl-2-(2-methylphenoxy)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide
N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
(1S)-N-(4-fluorophenyl)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
(4R,5R)-2-benzoyl-2-[4-(3-hydroxypropoxy)phenyl]-5-phenyl-3-spiro[1,5-dihydro-2-benzazepine-4,4-5H-oxazole]one
N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-oxanecarboxamide
N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
(1R)-N-(2-fluorophenyl)-1-[(2-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-(2-pyridinyl)methanone
(1R)-N-(4-fluorophenyl)-2-[(4-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-1,3-benzodioxole-5-carboxamide
[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-(2-pyridinyl)methanone
(1S)-N-(2-fluorophenyl)-1-[(2-fluorophenyl)-oxomethyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]carboxamide
methyl (1R,3S,12S,15S,19S)-18-ethenyl-19-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-20,21-dioxa-4,14-diazahexacyclo[10.8.1.02,17.03,11.03,15.05,10]henicosa-5,7,9-triene-2-carboxylate
(2S,3R,4S,5R,6R)-6-[[(3R,5R,8R,9S,10S,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-3,5-dihydroxy-4-sulfooxyoxane-2-carboxylic acid
methyl (1R,3S,12S,15S,18S,19S)-18-ethenyl-19-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-20,21-dioxa-4,14-diazahexacyclo[10.8.1.02,17.03,11.03,15.05,10]henicosa-5,7,9-triene-2-carboxylate
methyl (1R,3S,11R,12S,15S,18S,19S)-18-ethenyl-19-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-20,21-dioxa-4,14-diazahexacyclo[10.8.1.02,17.03,11.03,15.05,10]henicosa-5,7,9-triene-2-carboxylate
(1s,4as,6s,7s,7as)-4-({[(2r,3r,4s,5r,6r)-3,4-bis(acetyloxy)-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-6,7-dihydroxy-7-methyl-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-1-yl (2r)-2-methylbutanoate
3-methyl-1-[(2r,3s,4r,6r)-3,10,12-trihydroxy-4-(hydroxymethyl)-6-{[2,4,6-trihydroxy-3-(3-methylbutanoyl)phenyl]methyl}-5,7-dioxatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-9-yl]butan-1-one
(21s)-13,27-dimethoxy-15,29,31-trioxa-7,22-diazaoctacyclo[19.9.3.2¹⁶,¹⁹.1⁴,³⁰.1¹⁰,¹⁴.0³,⁸.0²⁵,³³.0²⁸,³²]heptatriaconta-1,3,7,10,12,14(37),16,18,25,27,30(34),32,35-tridecaene
(2r,3s)-4-[(6as)-6a-methyl-3-[(1e,3s)-3-methylpent-1-en-1-yl]-6,8-dioxofuro[2,3-h]isochromen-9-yl]-3-methyl-4-oxobutan-2-yl (2r)-2-methoxy-2-phenylacetate
methyl (1s,15s,16s,17s,21s)-15-hydroxy-17-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-18-oxa-3,13-diazapentacyclo[11.9.0.0²,¹⁰.0⁴,⁹.0¹⁶,²¹]docosa-2(10),4,6,8,19-pentaene-20-carboxylate
methyl (1s,14r,15s,16s,20s)-14-(hydroxymethyl)-16-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,18-pentaene-19-carboxylate
(3s)-5-[(3s)-10-hydroxy-7,9-dimethoxy-3-methyl-1h,3h,4h-naphtho[2,3-c]pyran-5-yl]-7,9-dimethoxy-3-methyl-1h,3h,4h-naphtho[2,3-c]pyran-10-ol
(2r)-1-(2,4-dihydroxy-3,5-dimethyl-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}phenyl)-2-methylbutan-1-one
[5-({4,5-dihydroxy-2-[4-(2-hydroxyethyl)-2-methoxyphenoxy]-6-(hydroxymethyl)oxan-3-yl}oxy)-3,4-dihydroxyoxolan-3-yl]methyl 2-methylbutanoate
[2-isopropyl-3,5-dimethyl-4,6-bis({[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy})phenyl](methylsulfanyl)methanone
methyl 7-methyl-6-[(5-phenylpenta-2,4-dienoyl)oxy]-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7h,7ah-cyclopenta[c]pyran-4-carboxylate
(1s,4as,6s,7s,7as)-6-(acetyloxy)-4-({[(2r,3r,4s,5s,6r)-3-(acetyloxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-7-hydroxy-7-methyl-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-1-yl 3-methylbutanoate
(2r,3s)-4-[(6as)-6a-methyl-3-[(1e,3s)-3-methylpent-1-en-1-yl]-6,8-dioxofuro[2,3-h]isochromen-9-yl]-3-methyl-4-oxobutan-2-yl (2s)-2-methoxy-2-phenylacetate
(9r,10r,11r)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-11-yl (2e)-3-phenylprop-2-enoate
(1r,2s,3r)-2-(3,5-dihydroxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-1-[(4-hydroxy-3-methoxyphenyl)(methoxy)methyl]-2,3-dihydro-1h-indene-4,6-diol
1,2-dehydroapateline
{"Ingredient_id": "HBIN000777","Ingredient_name": "1,2-dehydroapateline","Alias": "NA","Ingredient_formula": "C34H30N2O5","Ingredient_Smile": "CN1CCC2=CC(=C3C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7=NCCC8=CC(=C(O4)C=C87)O3)O)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4876","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3α-dihydrocadambine
{"Ingredient_id": "HBIN007940","Ingredient_name": "3\u03b1-dihydrocadambine","Alias": "3alpha-dihydrocadambine","Ingredient_formula": "C27H34N2O10","Ingredient_Smile": "COC(=O)C1=COC(C2C1CC3C4=C(CCN3CC2O)C5=CC=CC=C5N4)OC6C(C(C(C(O6)CO)O)O)O","Ingredient_weight": "546.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15059;SMIT18381","TCMID_id": "23513;5549","TCMSP_id": "NA","TCM_ID_id": "8185","PubChem_id": "162138","DrugBank_id": "NA"}
3-beta-isodihydrocadambine
{"Ingredient_id": "HBIN008273","Ingredient_name": "3-beta-isodihydrocadambine","Alias": "3beta-isodihydrocadambine; 3\u03b2-isodihydrocadambine","Ingredient_formula": "C27H34N2O10","Ingredient_Smile": "COC(=O)C1=COC(C2C1CC3C4=C(CCN3C2CO)C5=CC=CC=C5N4)OC6C(C(C(C(O6)CO)O)O)O","Ingredient_weight": "546.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT18369;SMIT16026","TCMID_id": "23461;31346;11374","TCMSP_id": "NA","TCM_ID_id": "8174","PubChem_id": "188431","DrugBank_id": "NA"}